Information on the Target

Elyan Partners ("Elyan") has entered into exclusive negotiations to acquire a controlling stake representing 52.17% of ONCODESIGN from its primary shareholders. This acquisition is contingent upon the completion of the announced separation of ONCODESIGN's two business units: "Service" and "Biotech," as well as the absence of events that could negatively affect ONCODESIGN's operational continuity. The acquisition will involve the holding company PCG, founded by Philippe Genne, who is also the CEO and Founder of ONCODESIGN, as well as certain members of the Executive Committee, reinvesting in the acquiring entity. Genne will continue to support the development of ONCODESIGN Service (ODS) as a shareholder and Chairman of the Supervisory Board of the acquisition holding.

Industry Overview in France

The pharmaceutical services sector plays a crucial role in addressing societal needs for improved quality of life by contributing to the development of new therapies. Historically, this industry has proven resilient amid various economic and health crises over the past decades. It is projected to continue its growth due to an increasing number of molecules being tested annually and greater outsourcing of services by pharmaceutical companies, particularly biotechs.

ONCODESIGN's Service Business Unit is globally recognized for its expertise in preclinical evaluation and concept proof of new experimental therapies in oncology and immune inflammation, as well as its capabilities in medicinal chemistry, pharmacology imaging, molecular radiotherapy (MRT), pharmacokinetics, bioanalysis, and humanized models. Led by Fabrice Viviani, the management team has been instrumental in not just developing the Service BU, but also in expanding both the number and quality of external clients through an integrated multidisciplinary service offerings in Drug Discovery and stand-alone services, providing clients a premium

View Original Article